Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Meriofert is a gonadotropin used to address reproductive disorders that involve insufficient endogenous LH and FSH activity.

• Infertility due to hypogonadotropic hypogonadism: supports follicular development and ovulation in patients with deficient gonadotropin secretion.
• Assisted reproductive technology (e.g., IVF): enhances oocyte maturation and improves cycle outcomes when combined with controlled ovarian stimulation.
• Induction of ovulation: facilitates the development of a dominant follicle to trigger ovulation in anovulatory women.

• Luteinising Hormone and Follicle‑Stimulating Hormone bind to their respective LH and FSH receptors on gonadal cells, activating intracellular cyclic AMP pathways. This stimulates steroidogenesis and gametogenesis, promoting follicular growth, estrogen production, and final oocyte maturation, thereby enabling ovulation and supporting fertility.

Adverse reactions may occur with any injectable gonadotropin therapy.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the administration site.
• Abdominal discomfort: transient bloating or mild cramping.
• Headache: occasional mild to moderate headache.
• Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects

• Ovarian hyperstimulation syndrome: excessive ovarian response requiring medical monitoring.
• Thromboembolic events: rare clot formation in veins or arteries.
• Severe allergic reaction: anaphylaxis or systemic urticaria.
• Multiple pregnancy: increased risk of twins or higher-order gestations.

Prior to initiating therapy, clinicians should evaluate patient suitability and monitor response closely.

• Assess baseline gonadotropin levels: confirm deficiency before treatment.
• Monitor ovarian response: use ultrasound and hormone assays to avoid overstimulation.
• Review contraindications: avoid in active malignancy or uncontrolled endocrine disorders.
• Counsel on signs of hyperstimulation: educate patients to report abdominal pain, rapid weight gain, or shortness of breath.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may modify efficacy or safety of Meriofert.

Major Interactions (Avoid)

• Concurrent use with GnRH agonists that may cause excessive gonadotropin surge.
• Use with estrogen‑containing contraceptives: may reduce intended ovulatory effect.
• Co‑administration with anticoagulants: increased risk of injection‑site bleeding.

Moderate Interactions (Monitor Closely)

• Combined ovarian stimulation protocols: require close hormone level monitoring.
• Concomitant corticosteroids: may mask early allergic reactions.
• Use with other fertility agents: adjust dosing based on response.